This thickening prevents the ventricle from expanding, and in turn reduces its pumping capacity and blocks blood flow out of the ventricle, causing oHCM
MyoKardia shared interim data from the PIONEER Open-Label Extension, or OLE, study of mavacamten for the treatment of symptomatic oHCM
. Twelve of twenty patients with oHCM
who previously completed MyoKardia's Phase 2 PIONEER-HCM trial have enrolled in PIONEER-OLE, and seven patients have completed a twelve-week assessment.
EXPLORER-HCM is a multi-national randomized double-blind study that will enroll approximately 220 patients with symptomatic oHCM
. Patients will be randomized on a 1:1 basis to receive either mavacamten or placebo for a 30-week treatment period.
MyoKardia announced positive results from the Phase 2 PIONEER-HCM clinical study of the investigational agent mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM
) patients, including results from a low-dose patient cohort, which studied once-daily 2mg and 5mg oral doses of mavacamten.